MX2021014161A - Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. - Google Patents

Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Info

Publication number
MX2021014161A
MX2021014161A MX2021014161A MX2021014161A MX2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A MX 2021014161 A MX2021014161 A MX 2021014161A
Authority
MX
Mexico
Prior art keywords
syndrome
methods
sjã
gren
bruton
Prior art date
Application number
MX2021014161A
Other languages
English (en)
Spanish (es)
Inventor
Martin Kaul
Bruno Bieth
Buck Stefan De
Souvik Bhattacharya
Maciej Cabanski
Bruno Cenni
Arvind Kinhikar
Andrijana Radivojevic
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021014161A publication Critical patent/MX2021014161A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021014161A 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. MX2021014161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851994P 2019-05-23 2019-05-23
PCT/IB2020/054754 WO2020234781A1 (en) 2019-05-23 2020-05-20 Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2021014161A true MX2021014161A (es) 2022-01-04

Family

ID=70918750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014161A MX2021014161A (es) 2019-05-23 2020-05-20 Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.

Country Status (23)

Country Link
US (2) US12383556B2 (enExample)
EP (2) EP3972603B1 (enExample)
JP (2) JP7765970B2 (enExample)
KR (1) KR20220011652A (enExample)
CN (1) CN113811301A (enExample)
AU (2) AU2020278236C1 (enExample)
BR (1) BR112021023110A2 (enExample)
CA (1) CA3137271A1 (enExample)
CL (1) CL2021003034A1 (enExample)
DK (1) DK3972603T3 (enExample)
ES (1) ES3004516T3 (enExample)
FI (1) FI3972603T3 (enExample)
HR (1) HRP20241584T1 (enExample)
HU (1) HUE069020T2 (enExample)
IL (1) IL287745B2 (enExample)
LT (1) LT3972603T (enExample)
MX (1) MX2021014161A (enExample)
PL (1) PL3972603T3 (enExample)
PT (1) PT3972603T (enExample)
RS (1) RS66195B1 (enExample)
SI (1) SI3972603T1 (enExample)
TW (1) TWI857060B (enExample)
WO (1) WO2020234781A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor
EP4284344A1 (en) * 2021-01-26 2023-12-06 Novartis AG Pharmaceutical composition
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
CA3239276A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102875105B1 (ko) 2023-04-03 2025-10-21 주식회사 사이알바이오 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0213100A (pt) 2001-10-05 2004-11-30 Combinatorx Inc Combinações para o tratamento de distúrbios imuniinflamatórios
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
HRP20211845T1 (hr) 2015-12-16 2022-03-04 Boehringer Ingelheim International Gmbh Derivati bipirazolila korisni za liječenje autoimunih bolesti
US10570118B2 (en) * 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
US10874741B2 (en) 2017-08-28 2020-12-29 Spectrix Therapeutics, LLC Compound to treat Sjogren's syndrome
EP3704158A1 (en) 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
US12383556B2 (en) 2019-05-23 2025-08-12 Novartis Ag Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
PL3972603T3 (pl) 2025-02-03
BR112021023110A2 (pt) 2022-04-12
IL287745A (en) 2021-12-01
DK3972603T3 (da) 2024-12-02
EP4442321A2 (en) 2024-10-09
SI3972603T1 (sl) 2025-02-28
AU2020278236B2 (en) 2025-08-07
RS66195B1 (sr) 2024-12-31
EP4442321A3 (en) 2025-01-01
JP2022533968A (ja) 2022-07-27
PT3972603T (pt) 2024-11-26
FI3972603T3 (fi) 2024-12-04
US20220175772A1 (en) 2022-06-09
JP7765970B2 (ja) 2025-11-07
TW202110451A (zh) 2021-03-16
AU2020278236C1 (en) 2026-02-26
CL2021003034A1 (es) 2022-09-09
WO2020234781A1 (en) 2020-11-26
TWI857060B (zh) 2024-10-01
KR20220011652A (ko) 2022-01-28
EP3972603B1 (en) 2024-09-04
EP3972603A1 (en) 2022-03-30
HRP20241584T1 (hr) 2025-01-31
HUE069020T2 (hu) 2025-02-28
US12383556B2 (en) 2025-08-12
JP2025165957A (ja) 2025-11-05
CN113811301A (zh) 2021-12-17
US20250339428A1 (en) 2025-11-06
AU2020278236A1 (en) 2022-01-06
IL287745B2 (en) 2026-02-01
IL287745B1 (en) 2025-10-01
CA3137271A1 (en) 2020-11-26
ES3004516T3 (en) 2025-03-12
AU2020278236A8 (en) 2022-04-28
LT3972603T (lt) 2024-12-10
AU2025263830A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2019012884A (es) Terapia de combinacion.
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2018016330A (es) Combinaciones para tratamiento del cáncer.
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
MX2025014865A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib
CO2026005447A2 (es) Compuesto de glp-1, y método de preparación y uso del mismo
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
EA202190360A1 (ru) Комбинированная терапия
MX2024010392A (es) Remibrutinib para el uso en el tratamiento de hidradenitis supurativa.
MX2021016090A (es) Lemborexant para el tratamiento de problemas del sueño.